Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 14/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CCND2 | P30279 | 1/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4239474 | 0.89 | CSNK1A1 (0.52) | GAAPKMCSNK1A1CDK4CCND1 | |
| SCHEMBL3967522 | 0.81 | IKBKB (0.46) | BRAFCDK4CCND1CCND2CCND3 | |
| SCHEMBL6073777 | 0.80 | BRAF (0.43) | BRAFCSNK1A1CDK4CCND1CCND2 | |
| SCHEMBL3969880 | 0.78 | CDK4 (0.56) | CDK4CCND1CCND2CCND3BRD4 | |
| SCHEMBL3971261 | 0.78 | SYK (0.62) | CDK4CCND1BRD4 | |
| SCHEMBL5312797 | 0.76 | PTK2 (0.41) | GAAPKMCSNK1A1CDK4CCND1 | |
| SCHEMBL2632915 | 0.74 | MDM2 (0.67) | GAAPKM | |
| SCHEMBL3970439 | 0.74 | SYK (0.50) | CDK4CCND1CCND2CCND3BRD4 | |
| SCHEMBL3974670 | 0.72 | PTK2 (0.49) | BRAFCDK4CCND1CCND2CCND3 | |
| SCHEMBL6074500 | 0.71 | PIK3CA (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | claimed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | claimed |
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1080092-B1 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | DOBRUSIN ELLEN MYRA (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | CCNI, CCNH, CCNA1 | BRAF 302/4885GAA 3637/4885PKM 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.